Suboxone vs. Methadone vs. Vivitrol: Choosing the Right Medication for Opioid Use Disorder in NYC

There are three FDA-approved medications for opioid use disorder: buprenorphine, sold as Suboxone, Zubsolv, and others, and as the long-acting injection Sublocade; methadone; and naltrexone, sold as the monthly injection Vivitrol. All three work. None of them is universally the right answer. The right one for any given patient depends on their pharmacological situation, their life circumstances, and what kind of treatment structure actually fits into their week.

What follows is an honest breakdown of how the three differ, written for patients and family members trying to make this decision in New York City.

The quick comparison

Now the longer version, because the table flattens distinctions that matter.

Suboxone (buprenorphine)

Buprenorphine is the medication most NYC patients end up on, and for good reasons.

It's a partial opioid agonist, which means it binds to the same brain receptors that heroin, fentanyl, and prescription opioids bind to -- but activates them only partially. This produces three effects that together explain its dominant role in modern OUD treatment: cravings and withdrawal are quieted, full opioids can no longer get to the receptors so euphoria from other opioids is largely blocked, and there is a "ceiling" on respiratory depression that makes fatal overdose far less likely than with methadone or fentanyl.

Practically, buprenorphine is the most flexible option. Since the X-waiver was eliminated by federal law in 2023, any clinician with a standard DEA registration can prescribe it. That means patients can be treated in regular medical offices -- and increasingly via telehealth -- rather than at specialized clinics. In New York, telehealth flexibilities introduced during COVID have been preserved and expanded, so an initial induction can often happen from home.

The main constraint with buprenorphine is the induction. Because it has very high affinity for the opioid receptor but only partially activates it, starting buprenorphine while a full opioid is still on the receptor will displace that opioid and abruptly drop the patient into withdrawal -- a phenomenon called precipitated withdrawal. To avoid this, traditional induction requires the patient to be in mild-to-moderate withdrawal already, roughly 12-24 hours after a short-acting opioid, longer for fentanyl or methadone. For patients using fentanyl, where the drug lingers in fatty tissue, this window can be tricky and may require a "low-dose" or "microdose" induction protocol. Any reasonable clinic will walk patients through this individually.

Who Suboxone tends to fit best: patients who want flexibility, discretion, the ability to keep working, telehealth options, and the lowest overdose risk profile of the three medications.

Methadone

Methadone has been used for opioid use disorder for over fifty years, and the evidence base supporting it is, if anything, even larger than buprenorphine's. It is a full mu-opioid agonist -- meaning it activates the receptor fully, like heroin or oxycodone do, but with a long half-life and stable pharmacokinetics that prevent the peak-and-crash cycle of misuse.

For patients with severe, long-standing opioid use disorder -- especially those who have not responded adequately to buprenorphine -- methadone often works when nothing else does. It does not have buprenorphine's ceiling effect, which is both its limitation, higher overdose risk, and its therapeutic strength, sufficient receptor activation for the most heavily dependent patients.

The catch is structural. Federal law requires that methadone for opioid use disorder be dispensed only at licensed Opioid Treatment Programs -- the "methadone clinics" patients sometimes encounter on their daily commute. New patients typically need to come in every day, often early in the morning, for observed dosing. Take-home privileges accumulate slowly with stability and clean drug screens. For some patients this structure is helpful. For patients with jobs, childcare, or non-traditional schedules, it can be a serious barrier. NYC has a relatively dense network of OTPs, but the time commitment is real.

Who methadone tends to fit best: patients with severe or long-duration opioid use disorder, patients who have not stabilized on buprenorphine, and patients for whom a structured daily program is helpful rather than a hindrance.

Vivitrol (naltrexone)

Vivitrol is the outlier of the three. It is not an opioid at all -- it is an opioid antagonist, meaning it blocks the receptor without activating it. If a patient on Vivitrol uses heroin or fentanyl, the drug essentially cannot connect to its target, so there is no high.

This sounds appealing in principle. The challenge is the entry barrier. Because Vivitrol blocks the receptor, starting it while any opioid is on board precipitates severe withdrawal. The standard protocol requires the patient to be fully opioid-free for 7-10 days before the first injection. For most patients with active opioid use disorder, getting through those 7-10 days unaided is the hard part. Without medication coverage, that period is exactly when relapse risk is highest.

The data also reflect this. In head-to-head trials, naltrexone has comparable outcomes to buprenorphine for patients who successfully start it, but a substantially lower proportion of patients are able to start at all. Vivitrol shines as a maintenance medication for patients who have already completed a detox or come out of an inpatient setting, or who specifically want a non-opioid medication. It is rarely the right first move for someone using fentanyl on the street today.

Who Vivitrol tends to fit best: patients who have already detoxed, often through an inpatient program, jail, or controlled environment; patients with strong preference against any opioid medication; and patients in professions where any opioid use, even therapeutic, would be a problem.

How access actually works in NYC

A few things worth knowing if you are navigating this for the first time:

• Insurance. Medicaid, Medicare, and essentially all major commercial insurers in New York cover all three medications. Out-of-pocket costs are usually minimal. If your plan throws up a prior-authorization requirement, a competent clinic should handle that for you.
• Telehealth. Buprenorphine telehealth flexibilities, originally introduced during COVID, have been extended and codified for the foreseeable future. For most patients, the entire treatment process -- from initial evaluation to ongoing maintenance -- can happen by video. Methadone still requires in-person dosing at an OTP. Vivitrol still requires in-person injection.
• Confidentiality. Substance use disorder treatment records are protected by HIPAA and by additional federal regulations, 42 CFR Part 2, that go further than standard medical confidentiality. Your employer, your family, and your insurer's general claims data do not see the clinical details of your treatment.
• Where to start. If you are not sure which medication is right for you, the practical answer is to start by talking to a clinician -- preferably one who prescribes all three, or who can refer you to a methadone OTP if that is the right fit. The choice should be made with you, not handed down to you, and a good clinician will spend the time on this conversation.